Insider trade

Moderna (MRNA): CEO exercised options on 499K shares

Stephane Bancel, CEO at Moderna, reported an option exercise of 499K shares.

499K
Shares · @ $19.15
Traded
Aug 5, 2026
Filed
Aug 7, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

The company's last weighty Form 8-K report up to this date: reported its results, 5 days earlier (Jul 31, 2026). The first one after it: signed an important agreement, 22 days later (Aug 27, 2026).

  1. InsiderOfficer sold ~$174K of MRNA shares in the open market
  2. InsiderOfficer sold ~$2.74M of MRNA shares in the open market
  3. Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On July 6, 2026 , the Board of Directors (the “Board”) of Moderna, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”), appointed Michael McDonnell to the Board, effective July 8, 2026.”
  4. InsiderOfficer sold ~$3.61M of MRNA shares in the open market
  5. 5% stakeBAILLIE GIFFORD & CO reported a passive stake (13G) of 4.6%
  6. Company filing · Form 8-K · ResultsReported its results
  7. Insider · 1 personInsiders: 4 sales (~$28.7M)

What came next

  1. 5% stakeFMR LLC reported a passive stake (13G) of 13.1%
  2. 5% stakeCapital World Investors reported a passive stake (13G) of 5.6%
  3. Congress · 1 personMembers of Congress: 1 purchase, 1 sale
  4. Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 2 more items)
  5. InsiderOfficer sold ~$486K of MRNA shares in the open market
  6. Insider · 1 personInsiders: 2 sales (~$4.7M)
  7. InsiderOfficer sold ~$5.81M of MRNA shares in the open market
  8. InsiderOfficer sold ~$5.88M of MRNA shares in the open market
  9. CongressDisclosed partial sale of MRNA — reported range $1,001 - $15,000
  10. Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On September 30, 2026, Moderna, Inc. (“Moderna” or the “Company”) announced the appointment of Juan Andres as its Chief Operating Officer (“COO”) effective October 5, 2026.”
  11. Insider · 1 personInsiders: 2 sales (~$8.4M)
  12. InsiderOfficer sold ~$8.64M of MRNA shares in the open market
  13. CongressDisclosed purchase of MRNA — reported range $1,001 - $15,000
  14. 5% stakeFMR LLC reported a passive stake (13G) of 14.8%
  15. Company filing · Form 8-K · ResultsReported its results
  16. Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations
  17. Company filing · Form 8-K · Executive changeChanged a top executive or board member“On November 13, 2026 , Moderna, Inc. (the “Company”) entered into a Transitional Services and Retirement Agreement (the “Retirement Agreement”) with Shannon Thyme Klinger, the Company’s Chief Legal Officer, that sets forth the terms of Ms. Klinger’s retirement from the Company.”
  18. InsiderOfficer sold ~$8.6M of MRNA shares in the open market
  19. Insider · 1 personInsiders: 3 sales (~$8.3M)
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Moderna

For Moderna, OQRO holds 19 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MRNA page.

Other recent filings by Stephane Bancel, Chief Executive Officer

The full history of Stephane Bancel, Chief Executive Officer is on the profile page.

How this filing works

Explore the data

Common questions

Which Moderna (MRNA) insider traded, and how much?

Stephane Bancel, CEO at Moderna, reported an option exercise of 499K shares. At $19.15.

When did it happen, and when was it made public?

Traded: Aug 5, 2026. Filed: Aug 7, 2026. That is 2 days between the two dates.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Moderna recently?

For Moderna, OQRO holds 19 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports and 1 fund holdings report (13F) dated in the last 90 days. They are listed on the MRNA page.

Does this mean MRNA stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Moderna

Everything OQRO holds on this company is on its MRNA page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data